HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

doi:10.1182/blood.2019895326

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Blood - 16 Jan 2020

Yue Lanzhu, Sharma Vasundhara, Horvat Nathan P, Akuffo Afua A, Beatty Matthew S, Murdun Cem, Colin Christelle, Billington Julia M R, Goodheart William E, Sahakian Eva, Zhang Ling, Powers John J, Amin Narmin E, Lambert-Showers Que T, Darville Lancia N, Pinilla-Ibarz Javier, Reuther Gary W, Wright Kenneth L, Conti Chiara, Lee Jennifer Y, Zheng Xiaozhang, Ng Pui Yee, Martin Matthew W, Marshall C Gary, Koomen John M, Levine Ross L, Verma Amit, Grimes H Leighton, Sotomayor Eduardo M, Shao Zonghong, Epling-Burnette Pearlie K

Abstract excerpt

Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2-driven diseases best exemplified by myeloproliferative neoplasms (MPNs). By using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, we discovered that HDAC11 rather than HDAC6 is necessary for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematopoiesis

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Janus Kinase 1

Share to Myeloproliferative Disorders

Share to Oncogenes

Share to STAT Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 31750881
DOI: 10.1182/blood.2019895326
PMCID: PMC6966930

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.PMID 31750881Read ↗

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?Semantic proximity Read ↗

Role of HDACs in normal and malignant hematopoiesisSemantic proximity Read ↗

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative DiseaseSemantic proximity Read ↗

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase InhibitorsSemantic proximity Read ↗

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic diseaseSemantic proximity Read ↗

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasmsSemantic proximity Read ↗

Histone deacetylase 6 in cancerSemantic proximity Read ↗

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cellsSemantic proximity Read ↗

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progressionSemantic proximity Read ↗

HDAC6: Tumor Progression and BeyondSemantic proximity Read ↗

A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarkerSemantic proximity Read ↗

Targeting HMGA1-driven leukemic transformation in myeloproliferative neoplasms with pacritinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.